Chronic kidney disease and end-stage renal failure strike one of every 10 Americans. The incidence is highest among people ages 65 and older, for whom the rate more than doubled between 2000 and 2008. As the population ages, this health care issue will become even more significant.
There is a need to eliminate unpromising drug candidates as early as possible. That is why MPI Research has built solid expertise in cutting-edge technologies so Sponsors can profile their candidates quickly and fully. In renal disorders, we offer models such as partial nephrectomies and STZ-induced diabetes. The causes of kidney diseases are varied, but MPI Research has the experience and skill to apply a variety of tools to assess potential new treatments.
Years combined experience
Studies performed in the past 2 years